



Initial Disclosure Statement

(OTC Pink: EMGE) OTC Pink

**For the year ended December 31, 2014
And the Three Months Ended
March 31, 2014**

**Dated:
July 1, 2015**

Table of Contents

Part A Initial Company Information	3
Item I Company History	
Item II. Company Headquarters	
Item II Company State of Incorporation	
Part B Share Structure	4
Item IV. Title and class of securities outstanding	
Item V. Par or stated value and description of the Company's securities.	
Item VI. The number of shares or total amount of the securities outstanding for each class of securities authorized.	
Part C Business Information	5
Item VII. The name and address of the transfer agent	
Item VIII. Nature of Business	
Item IX. Nature of products or services offered.	
Item X. Company Facilities	
Part D Management Structure and Financial Information	13
Item XI. Directors. Executive Officers and Control persons	
Item XII Financial information for the issuer's most recent fiscal period.	
Item XIII Financial information for the years ending December 31, 2014 and 2013	
Item XIV Beneficial Owners	
Item XV Company Professionals	
Item XVI Management's Discussion and Analysis or Plan of Operation.	
Part E Issuance History	20
Item XVII. List of securities offerings and shares issued for services in the past two years.	
Part F Exhibits	21
Exhibit A	
Financial Statements through March 31, 2015	
Exhibit B	
Financial Statements for the year ending December 31, 2014	
Exhibit C	
Articles of Incorporation	
Exhibit D	
Corporate By-laws	
Item XXI Issuer's Certifications	

Part. A General Company Information

Item I: Company History

We were incorporated, under the name Rolling Stone Retirement Community, Inc. on April 27, 2006, under the laws of the State of Nevada. Pursuant to an agreement dated January 18, 2007, John V. Cappello and Associates, Inc., (JVC), acting as an agent for its designees purchased 95% of the outstanding shares of the issuer's predecessor, Rolling Stone Retirement Community, Inc., which it then distributed to its designees. Upon purchase, John Cappello became our sole officer and director and our business plan became the development and distribution of nutritional and dietary products developed by Dr. Cappello. On May 20, 2007, we amended our corporate charter to change our name from "Rolling Stone Retirement Community, Inc." to "Emergent Health Corp." Our common shares are quoted by the OTC Markets OTC Link with an OTC Pink Tier under the symbol "EMGE".

Pursuant to an agreement dated January 18, 2007, John V. Cappello and Associates (JVC) acting as an agent for its designees purchased 95% of the outstanding shares of our predecessor, Rolling Stone Retirement Community, Inc., which it then distributed to its designees.

On July 9, 2008, we authorized a 50:1 reverse split of its common shares, effective July 19, 2008. A new CUSIP Number 29100Q 209 was granted by NASDAQ. This action reduced the outstanding common shares of the Issuer from 10,279,216 to 206,101.

On December 31, 2009, an 11-10 forward split became effective increasing our outstanding common shares to 21,786,711.

On November 12, 2013, Emergent President, John V. Cappello (JVC), entered into a Stock Purchase Agreement with Parcae Capital Corporation (Parcae), a Massachusetts company, and Clover Capital Corp (Clover), a Pennsylvania company controlled by Gregory McCauley. Parcae and Clover agreed to purchase 11,880,000 shares of common stock from JVC for \$800,000.

On May 29, 2014, we entered into a consulting agreement with Parcae and Clover. We issued 15,000,000 common shares in total to Parcae and Clover for their services.

On August 27, 2014, the Stock Purchase Agreement closed and Stephen Hussey and Kimberly Halvorson joined our management team. On September 13, 2014 John Launie was appointed the Company's Chief Financial Officer.

In December 2014, Scott Maguire Chairman, John Launie, Robert S. McCoy Jr., Dr. David P. Jones, and Kevin Harrington were elected to our Board of Directors. In connection therewith, on January 14, 2015, Stephen Hussey resigned as our chief executive officer, and on January 21, 2015 John Launie was appointed as our new President and Chief Executive Officer.

Mr. Launie has subsequently left the company and is no longer a director as of June 2015 and Chris Swenson was appointed as our new Chief Executive Officer and Director.

Item II. COMPANY HEADQUARTERS

Emergent Health Corp.

2424 North Federal Highway

Boca Raton, FL 33431

Phone: 866-427-6143

Website: <http://www.emergenthealth.com>

ITEM III. State of Incorporation:

Nevada

Part B Share Structure:

ITEM IV: Title and class of securities outstanding:

Common Stock

The Company has 200,000,000 common shares par value \$0.001 authorized of which 40,730,000 shares are outstanding with an estimated 4,450,154 in the free trading float. There are 20,000,000 preferred shares authorized with none outstanding.

Trading Symbol: EMGE

Item V. Par Value and Description of Company's securities

Par Value \$0.001 per share

Item VI. The number of shares or total amount of the Securities Outstanding

The Company is authorized to issue 200 million shares of common stock of which 40,730,000 shares of our common stock is issued and outstanding.

There are no outstanding preferred shares.

As to our Common Stock:

Holders of the Company's common stock are entitled to one vote for each share of common stock on any matters brought to a vote of the shareholders.

Holders of the Company's common stock are entitled to dividends if declared in the sole and absolute discretion of the Company's Board of Directors. Since Inception, the Company has not made any dividend payments.

There are no provisions in the Company's Bylaws or Certificate of Incorporation or any amendments thereto which would delay, defer or prevent a change in control.

As to our Preferred Shares:

The Company is authorized to issue twenty million shares of preferred stock none of which have been issued. The Board of Directors reserves the right to designate the class and rights and preferences of any class of preferred shares.

Part C Nature of Business

Item VII: The name and address of our transfer agent is:

**Olde Monmouth Stock Transfer
200 Memorial Parkway
Atlantic Highlands, NJ 07716**

www.oldermonmouth.com

[Matt Troster](#) - Transfer Agent
Phone # (732) 872-2727 ext. 101
Email: Matt@oldermonmouth.com

[John Christopher Troster](#) - President
Phone: 732-872-2727 ext. 102
Email: Chris@oldermonmouth.com

Item VIII: Nature of Business

COMPANY OVERVIEW

Our Business

We distribute 12 nutritional and dietary products through an exclusive licensing agreements with Dr. John Cappello. Each product we offer is based upon the research of our consultant, Dr. John Cappello. Our products are based upon suggestions from our distributors, customers, and from product and market research he conducts on an ongoing basis. Our products have not been confirmed in any respect by the U.S. Food and Drug Administration or any other governmental agency, and may nor produce the results intended. We have approximately 950 distributors/customers.

On August 27, 2014 we entered a licensing agreement with Dr. Cappello. The License Agreement grants us the exclusive rights to market and sell each of the licensed products in the United States. The License Agreement shall continue up to the expiration of the last to expire of any patent rights granted under the License. We pay Dr. Cappello a royalty based upon the Net Sales of each product. Net Sales is defined as gross revenues excluding taxes and freight.

The following table sets forth the royalty payments due Dr. Cappello.

Gross Sales:	Royalties:
<input type="checkbox"/> Up to \$1million	5%
<input type="checkbox"/> \$1 million to \$2 million	4%
<input type="checkbox"/> \$2 million to \$3million	3%
<input type="checkbox"/> \$3 million to \$5million	2%
<input type="checkbox"/> Greater than \$5 million	1%

Royalty payments are due quarterly. The Company is required to provide Dr. Cappello (the “Licensor”) with quarterly sales reports. Further, in the event that sales of any licensed product is not 15% greater than the sales from the prior year, the Licensor, in his sole discretion may terminate the license for the underperforming product or convert the license from an exclusive license to a non-exclusive license. The Company may maintain an exclusive license for any underperforming product by paying Licensor all royalties that would otherwise have been due had the underperforming asset achieved a 15% increase over the prior year’s sales. We have not made the minimum royalty payments on several products.

Item IX: Nature of Business

Our Products

Our MultiStem contains all the major multi vitamins & minerals including vitamin D. We sell our MultiStem to distributors at the price of \$29.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Our Hungarest® Diet & Energy Aid contains L-Phenylalanine, Phenylalanine and L-Tryptophan. It is designed to suppress the appetite, improve mood and increase energy. We sell Hungarest® Diet & Energy aid to distributors at the price of \$29.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Vita-Stim Stem Cell Nutrition contains Anhydrous Trimethylglycine and is designed to stimulate adult stem cells and improve overall health and wellness. We sell our Vita-Stim Stem Cell Nutrition to distributors at the price of \$39.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

NutraCan Nutritional Support is a powder that can be mixed with juice or food and contains our MultiStem product as well as provides ellagitannin support. We sell our NutraCan to distributors at \$79.95 for a 370 gram container. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Three In One™ Miracle Serum™ contains methylsulfonylmethane (MSM) and is a serum applied externally with the object to provide pain relief to sore joints and muscles, invigorate scalp and tone the face. We sell our Three In One™ Miracle Serum™ to distributors at the price of \$19.95 for a 2 ounce bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Neuvitale™ contains Anhydrous Trimethylglycine and is a faster acting and more advanced form of our Vita-Stim product. We sell our Neuvitale™ to distributors at the price of \$69.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Cardio Forte™ is a proprietary Arginine complex formulation designed to assist numerous body functions and as an overall health tonic. We sell our Cardio Forte™ to distributors at the price of \$44.95 for a 450 gram bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Emergent O₂™ Water Oxygenator is an oxygen additive to bottled water. The product is designed to hydrate cells and tissues and detoxify the body. We sell our Emergent O₂™ Water Oxygenator to distributors at the price of \$29.95 for a 2 ounce bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

NeuStem™ Cell Helper is designed to stimulate adult stem cells, promote the immune system and provide antioxidants and anti-inflammatory ingredients. We sell our NeuStem™ Cell Helper to distributors at the price of \$39.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Infinity™ Anti-Aging & Body Repair Support contains curcumin, silymarin, resveratrol, astragalus polysaccharides, L-carnosine, trimethylglycine, and vitamin C and is designed to activate SIRT-1 anti-aging genes, fight free radicals, and protect from oxidative stress which can accelerate telomere shortening. We sell our Infinity™ Anti-Aging to distributors at the price of \$79.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Infinity Plus™ Anti-Aging & Body Repair Support contains curcumin, silymarin, resveratrol, astragalus polysaccharides, L-carnosine, trimethylglycine, and vitamin C and is designed to activate SIRT-1 anti-aging genes, fight free radicals, and protect from oxidative stress which can accelerate telomere shortening. The Infinity Plus™ product adds a proven RNA/DNA source to the formulation. We sell our Infinity Plus™ Anti-Aging to distributors at the price of \$79.95 for a 60 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Veral™ – The Manly Aid contains calcium, zinc, muira puama, maca, nettle, longjack, ginkgo, chrysin, tribulus-terrestris and black pepper. It is a men's sexual health product designed to help maintain healthy testosterone levels. We sell our Veral™ – The Manly Aid to distributors at the price of \$49.95 for a 120 capsule bottle. Distributors receive commissions of between 2.5% and 20% within 30 days after purchase.

Research and Development

All of our research to date has been done by Dr. John Cappello, our Chief Science Advisor. Dr Cappello is a chemist. He earned a bachelor's degree in engineering from Philadelphia University, a Master's Degree in Business Administration from Drexel University and a Doctor of Osteopathic Medicine Degree from Philadelphia College of Osteopathic Medicine.

Suppliers

During the years ended December 31, 2014 and December 31, 2013 one supplier provided more than 80% of our finished products. . We do not believe that the loss of this supplier would have a material adverse effect on our financial condition or results of operations as there are other suppliers in the marketplace that would be a suitable alternative.

We outsource our warehouse and fulfillment costs using the Stephen Gould Corporation, a third-party provider. This arrangement is done under a month to month contract and calls for a payment per order picked plus a monthly pallet storage fee, recorded under warehouse and fulfillment costs.

Sources and Availability of Raw Materials

We receive all of our raw materials from a single supplier We pay for raw materials ordered within 30 days after order.

The raw materials used by us are available from a variety of suppliers. We maintain a good relationship with our supplier and do not anticipate that it will terminate its relationship with us in the near term. In the event, we are unable to obtain any of our raw materials from our supplier, we believe that we could obtain alternative sources of any raw materials from other suppliers. We do not have contracts with our supplier and we order our raw materials on an as-needed basis. We have not experienced any material adverse effect on our business as a result of shortages of raw materials or packaging materials used in of our products. An unexpected interruption or a shortage in supply of raw materials could adversely affect our business derived from these products.

Manufacturing

Raw materials are delivered to Bactolac Pharmaceuticals, Inc. who completes the finished products and delivers the finished product to Stephen Gould Corporation for fulfillment.

We do not have a written agreement with our manufacturer. Bactolac Pharmaceuticals manufacturers our products on an as-needed basis. In the event, that Bactolac Pharmaceuticals ceases to manufacture our products, we believe that we could obtain alternative manufacturers. We pay for product manufactured within thirty days after delivery of our product to Gould.

Multi-Level Marketing Program

Distributor Compensation Plan:

Our multi-level marketing compensation plan is designed to attract, retain and motivate our distributors. . Our plan has been carefully created to award success, encourage growth and development of a distributor's own organization (e.g. wide and deep) and fairly compensate each member. The generation pay provision is an exciting element of the plan that encourages down line training resulting in extended organizations.

Our compensation plan is designed to allow individuals to work at his/her own pace, with great potential for achieving financial goals. Distributors will be surrounded by up-lines and down-lines; they include people with experience, passion and the desire to help others. Financial potential is limited only by the distributor's goals and work ethics.

The objective of our compensation plan is to help distributors stay active far longer than the average two or three months, experienced by most other companies. The incentive is getting money in distributor's "pockets" the first day they join the network, while teaching them how 'People Helping People' can truly change their lives. We believe that our compensation plan will allow distributors to keep customers longer due to a simple weekly and bonus structure, innovative products, proven marketing techniques and effective training. Not only can they learn how to recruit people but training also focuses on a comprehensive understanding of the compensation plan and the financial benefits which promotes the building of a down-line organization.

Our compensation plan will pay out earned commissions that can equal as much as 50% to distributors every month. We offer an auto-ship program for distributors and customers.

Our compensation plan is a uni-level plan. The primary objective for the distributor is to produce volume within his/her organization and not to be concerned about specific numbers of distributors. The types of uni-level potential income include:

- i. Retail commissions.
- ii. Uni-level pay down through ten levels of your organization.
- iii. Generation pay which allows you to earn commission on your organization sales.
- iv. Leadership positions that share in a monthly bonus on all commissionable sales.
- v. Incentives whereby distributors participate in exotic trips and world-class events.

Marketing and Sales:

The emphasis of our marketing/sales plan will be to disseminate information on a cost effective basis to an ever growing organization. Our model intends to facilitate the process by attaining the skills and organizations of established leaders who have track records in a myriad number of other multi-level marketing organizations.

By immediately entering into a relationship with these leaders, credibility will be established among the targeted community.

The marketing plan includes:

1. Active campaign to targeted leaders and organizations
2. Development of website:
 - Front end design
 - Design for the 'Distributor Only' part of the website
 - Shopping cart Implementing a program where first time customers receive free product on their initial order.
3. Weekly conference calls for distributors
4. Creation of a marketing videos.
5. Public Relations events with executives, Board members, product roll-outs, and leaders.
6. Identify key leaders for the field organization and teach how to recruit
7. Prepare various product configurations for purchase
8. Create Training for:
 - Building your business (recruiting) through various vehicles, managing your business while motivating and guiding your organization of Distributors.
 - Seminars that will be combined with business training. These training seminars will be a revenue stream for the company and a requirement for advancement in rank by Distributors.
9. Prepare early recognition rewards/trips.
10. Prepare early brochures/product samples.
11. Establish regular pattern of press release
12. Prepare Press Kit.

Distributor Motivation and Training

We believe that motivation, inspiration and training are key elements in distributor success and that we and our distributor supervisors have established a consistent schedule of events to support these needs. We conduct training sessions to educate and motivate our distributors.

Distributor Development

We believe that the key contributing factors to our long-term growth and success are the recruitment of new distributors and retention of existing distributors. We are active in the development of distributors, including in the areas of recruitment, training, support, motivation and compensation.

We make the needs of our distributor a priority, in accordance with our stated corporate philosophy. We provide a high level of support services tailored to the needs of our distributors, including training meetings, educational and informative conference calls, ordering and distribution system, personalized customer service via telephone, the Internet and e-mail, 24-hour, seven days per week access to certain information through touch-tone phones and a liberal product return policy. Our support system includes a current database of all distributors and their upline and downline distributors. We also provide business development materials that we believe will increase both product sales and recruitment. We believe that enhancing a distributor's efforts through effective support mechanisms has been and will continue to be important to our success.

Management of Distributors

We take an active role in the management of our distributors. We restrict the statements and conduct of distributors by contractually binding distributors to abide by the Distributor Policies and Procedures (the "Policies and Procedures") promulgated by us. Each distributor receives a copy of the Policies and Procedures, which must be followed in order to maintain the distributor's status in the organization. Distributors are expressly forbidden from making any representation as to the possible earnings of any distributor, other than our approved statements indicating the range of actual earnings by all distributors and other required information, prepared in accordance with applicable law. Distributors are also prohibited from creating any marketing literature that has not been approved by us.

Ethical Considerations

We are a member of the Direct Selling Association ("DSA"), and we adhere to the code of ethics established by the DSA.

Intellectual Property

We are licensed to use the following patents and trademarks:

Title	Product	Application Number	Filing Date	Patent Number	Issue Date	Status
Dietary Supplements Including Glucan and Fulvic Acid	NeuStem™	14/207,050	3/12/2014	Pending	Pending	Pending
Dietary Supplements Including Ellagitannins and Ellagic Acid	ResoluCan™	13/757,744	2/2/2013	Pending	Pending	Pending
Compositions for Producing Satiety	Hungarest®	12/710,161	2/22/2010	Pending	Pending	Pending
Anti-Aging Formulations	Infinity™ Anti-Aging, Infinity Plus™ Anti-Aging	13/723,503	12/21/2012	8,945,532	2/3/15	Issued
Anti-Aging Formulations	Infinity™ Anti-Aging, Infinity Plus™ Anti-Aging	13/357,280	1/24/2012	8,906,361	12/9/2014	Issued
Formulations for Promoting Stem Cell Nutrition	JDI Multi™, Infinity™ Anti-Aging, Infinity Plus™ Anti-Aging™	13/425,563	3/21/2012	8,334,131	12/18/2012	Issued
Topical and Transdermal Treatments Using Urea Formulation		12/290,744	11/3/2008	7,803,357	9/28/2010	Issued
Blue-Green Algae Composition	Vita Stim, JDI Multi™	11/788,693	4/19/2007	7,473,427	1/6/2009	Issued
Topical and Transdermal Treatments Using Urea Formulation		11/590,037	10/30/2006	7,445,783	11/4/2008	Issued

Item X. Company Facilities

On September 19, 2014, we entered into a lease for approximately 3,882 square feet at 2424 North Federal Highway, Suite 257 Boca Raton, Florida. The term of the lease is for 66 months and runs from October 1, 2014 and expires on March 31, 2020. We are obligated to pay \$91,163 for annual rent in 2015. Rents increase by approximately 15% each year during the term.

Part D Management Structure:

Item XI. Directors, Executive Officers and Control Persons

Directors and Executive Officers

The following table sets forth the name, age, and position of our executive officers and directors. Executive officers are elected annually by our Board of Directors. Each executive officer holds his office until he resigns, is removed by the Board, or his successor is elected and qualified. Directors are elected annually by our shareholders at the annual meeting. Each Director holds his office until his successor is elected and qualified or his earlier resignation or removal.

Name	Age	Position
Chris Swenson	51	President, Chief Executive Officer, Director
David P. Jones, Ph.D.	66	Director
Robert S. McCoy, Jr.	76	Director
Kevin Harrington	57	Director
M. Scott Maguire	51	Director

Chris Swenson - Chief Executive Officer

Mr. Swenson brings over 25 years of financial experience to the Company. His areas of concentration include financial analysis, strategic planning, business development and budgeting.

Since 2014 Mr. Swenson has served as the Chief Financial Officer of Neuclear, Inc. From 2009 through 2013 he served as the Chief Financial Officer of CENX, Inc., from 2001 through 2008 he served as the Vice President of Finance at Neutral Tandem (now known as Inteliquent Corp.) Chris earned his BA from the University of New Hampshire and his MBA from Babson College.

Chris is a health and fitness enthusiast with a deep knowledge of the nutraceutical market. His finance background brings a depth of experience to growing companies.

David P. Jones, Ph.D. - Director

Since December 15, 2014, David P. Jones, Ph.D. has been our Director. Since January of 2000, Dr. Jones has been the Chief Executive Officer of Growth Ventures, Inc., an executive staffing firm and advisory firm.

In 1976, Dr. Jones received a Doctorate in Industrial Psychology and in 1974, he received a Master's Degree in Industrial Psychology from Bowling Green State University. Dr. Jones received a Bachelor's Degree in liberal arts in 1970 from Bowling Green State University.

As our Director, Dr. Jones brings his experience in employment relations and executive staffing.

Robert S. McCoy, Jr. – Director

Since December 17, 2014, Robert S. McCoy, Jr. has been our Director. Since December of 2003, Mr. McCoy has served as a Director of Krispy Kreme Doughnut Corporation, since October of

2003, he has served as a Director for Medcath Corporation and since March of 2006, he has served as a Director of Web.com.

In 1961, Mr. McCoy received a Bachelor's of Business Administration degree in from Western Michigan University.

As our Director, Mr. McCoy brings extensive leadership, risk-management, and financial experience gained during his career, which included roles as an accountant and as the Chief Financial Officer of two public bank holding companies.

Kevin Harrington – Director

Since December 23, 2014, Kevin Harrington has been our Director. Currently, Mr. Harrington is the CEO of Starshop, the first Mobile Shopping Channel in partnership with Sprint. Previously, Mr. Harrington appeared on the ABC series "Shark Tank" as a panel member and investor. Mr. Harrington is best known as the founder of "As Seen on TV" and as a pioneer in the infomercial industry.

Mr. Harrington attended the University of Cincinnati from 1976 to 1978.

M. Scott Maguire – Director

Since October 1, 2014, M. Scott Maguire has been our Director. From April of 2004, he has been the Chief Executive Officer of Xenetic Bioscience, Inc., a publicly traded company.

Mr. Maguire obtained his MBA from Babson Graduate School in 1993.

As our Director, Mr. Maguire brings his experience in public company management.

Involvement in Certain Legal Proceedings

No officer, director, or persons nominated for such positions, promoter or significant employee has been involved in the last ten years in any of the following:

- Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
- Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
- Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;
- Being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

- Having any government agency, administrative agency, or administrative court impose an administrative finding, order, decree, or sanction against them as a result of their involvement in any type of business, securities, or banking activity;
- Being the subject of a pending administrative proceeding related to their involvement in any type of business, securities, or banking activity; and/or
- Having any administrative proceeding been threatened against you related to their involvement in any type of business, securities, or banking activity.

Key Employees

Dr. John Cappello, Chief Science Advisor

Since August 2014, Dr. John Cappello has been our Chief Science Advisor. For the past five years prior to becoming our Chief Science Advisor, Dr. Cappello served as President and Treasurer of the company.

In 1967, Dr. Cappello received a Bachelor's Degree in Chemistry from Philadelphia University. In 1968, Dr. Cappello obtained a Master's Degree in Business Administration from Drexel University. In 1978, Dr. Cappello received his Doctor of Osteopathic Medicine Degree from Philadelphia College of Osteopathic Medicine.

Item XII: Financial Information for Company's most recent fiscal quarter.

The Financial Statements for the quarter ended March 31, 2015 are included with this report and marked Exhibit A.

Item XIII: Financial Information for the year ended December 31, 2013 and 2012

The Financial Statements for the year ended December 31, 2014 and 2013 are included with this report and marked Exhibit B.

Item XIV: Beneficial Owners

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding our shares of common stock beneficially owned as of July 01, 2015, for (i) each stockholder known to be the beneficial owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock options or Warrants or otherwise. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner's spouse or children.

For purposes of this table, a person or group of persons is deemed to have "beneficial ownership" of any shares of common stock that such person has the right to acquire within 60 days of the date of this Disclosure Statement.

Name and Address of Beneficial Owner	Amount of Beneficial Ownership	Direct Ownership	Indirect Ownership	Percentage of Class
<i>Executive Officers and Directors</i>				
David P. Jones, Ph.D., Director (3)	110,000	110,000		0.3%
Robert S. McCoy, Jr., Director	100,000	100,000		0.2%
Kevin Harrington, Director	900,000	900,000		2.2%
M. Scott Maguire, Director	100,000	100,000		0.2%
<i>Other 5% Holders</i>				
John Cappello, Chief Science Advisor (4)(8)	7,529,876	5,529,876	2,000,000	18.5%
Gregory McCauley (5)	7,669,550	7,669,550		18.8%
Francis Magliochetti(6)	4,000,000	500,000	3,500,000	9.8%
Emergent Health Management Group, LLC (7) (8)	4,455,000	4,455,000		10.9%
Steven Hussey, Former Chief Executive Officer (2)	5,984,550	5,984,550		14.7%
Total Shares owned by our officers and directors	1,210,000			3%

- (1) Based on 40,730,000 common stock issued and outstanding as of the date of this registration statement. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable.
- (2) Stephen Hussey, our former Chief Executive Officer and Director, holds 5,984,550 common shares indirectly held by Stephen Hussey IRA.
- (3) David P. Jones, Ph.D. purchased 10,000 common shares in an open market purchase on December 4, 2014, and received 100,000 shares on December 15, 2014 for services rendered.
- (4) Dr. John Cappello holds 5,529,876 common shares directly and holds 2,000,000 shares indirectly in the name of Castle Holding Corp., an entity controlled by him and Cappello's, Inc., a South Carolina Corporation he controls. This does include 415,800 shares held in escrow pursuant to a Stock Purchase Agreement dated August 27, 2014 between Parcae Capital Corp. and Clover Capital Corp, John Cappello and Cappello's Inc.
- (5) Gregory McCauley, our Corporate Counsel, holds 7,669,550 shares directly.
- (6) Francis Magliochetti holds 500,000 shares directly and 3,500,000 shares in the name of the FPM QTIP Trust. The trust has an independent trustee and Mr. Magliochetti is the sole beneficiary.
- (7) Kimberly Halvorson, a former employee, holds 2,160,675 shares which represents 48.5% of the shares held by Emergent Health Management Group, LLC.
- (8) Does not include any additional shares of common stock that may be issued pursuant to the fully ratchet anti-dilution provisions contained in the Stock Purchase Agreement entered into between Dr. Cappello, Parcae Capital and Clover Capital.

Involvement in Certain Legal Proceedings

None.

Family Relationships

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

Item XV. Company Professionals

Legal Counsel

Jeffrey G. Klein
301 Yamato Road
Suite 1240
Boca Raton, FL 33431
Office: (561)953-1126
Fax: (561)994-6693
Cell: (561)414-1640
jklein@jkleinlegal.com

Auditor

Anton and Chia, LLP
3501 Jamboree Road
Newport Beach, CA 92660
949-769-8905
infor@ancsecservices.com

Accountant

Yoshida & Solkolski, PC
20 Burlington Mall Road
Burlington, MA 01803
781-273-1010
Fax: 781-270-3532
www.yoshcpa.com

Item XVI. Management's Discussion and Analysis or Plan of Operation

Our marketing plan calls for a rebranding strategy with a targeted series of well- designed campaigns that have been successfully implemented previously and are being utilized currently by other direct sales companies. We are also currently recruiting senior sales executives to help implement this plan.

We have s a targeted demographic strategy within the Hispanic market. According to recently conducted research, the Hispanic community represents an untapped market. Already the largest minority in the U.S., their numbers continue to grow faster than any other group. Between 2000 and 2010, the Hispanic population grew by 43%, or four times the nation's 9.7% growth rate. We are recruiting seasoned direct selling Hispanic leaders who have expressed discontent with the way that most direct selling companies treat the needs of Hispanic entrepreneurs and customers. This includes, but is not limited to, producing all of the Cellaviv marketing materials and resources in Spanish.

Product Strategies

Cellaviv

This is the company's new direct selling division. We have decided to combine two specific, proven and cost effective strategies inside of this model to optimize growth in 2015. Cellaviv plans to implement a "gift card" marketing system that has been successful with a nutraceutical direct selling competitor.

Cellviver Shake

This is a new product formulation developed by Dr. Cappello. It is a shake that is currently in brand development for release in the first quarter of 2015. It is a multi-faceted beverage with dozens of nutrients including proteins, vitamins and minerals as well as antioxidants and phytonutrients designed to help detoxify and protect the body against free radical damage. The potential benefits of the product are weight loss, reduction in food cravings, increased energy and improved digestion and regularity.

Weight Loss Program

The Company is presenting a simple and effective weight loss program with the following products as part of a package: *Hungarest, Cellviver, Oomph Gum and SomniBurn.*

Individuals follow a simple routine of:

- 2 Hungarest in morning and in the afternoon
- 1 Cellviver Shake at noon
- 4 pieces of Oomph Gum per day
- 1 SomniBurn at bedtime

NutraCan

The second product is NutraCan and it is designed to serve as a nutritional adjunct to chemotherapy. It is scheduled for a launch as an OTC product.

The NutraCan Nutritional Support Product is a powder that can be mixed with juice or with food. It contains a one month supply at one scoop a day. One scoop contains ellagitannin support in addition to Stem Cell Nutrition. The NutraCan product contains both patent and patent pending formulations. It's mechanism of action can best be described as:

- Vitamin and Mineral support
- Stem Cell Nutrition support
- Ellagitannin support

PART E Issuance History

Item XVII . List of securities offerings and shares issued for services in the past two years

On November 12, 2013, Emergent President, John V. Cappello (JVC), experiencing poor health and recognizing the need to attract new management, entered into a Stock Purchase Agreement with Parcae Capital Corporation (Parcae), a Massachusetts company, and Clover Capital Corp (Clover), a Pennsylvania company controlled by Gregory McCauley. Parcae and Clover agreed to purchase 11,880,000 shares of common stock from JVC for \$800,000, restructure the company, install new management, update the Company's books and records, have an audit of the Company's 2012 and 2013 financial statements performed and facilitate the filing of an S-1 Registration Statement with the SEC.

On May 29, 2014, we entered into a consulting agreement with Parcae and Clover. We issued 15,000,000 common shares in total to Parcae and Clover for their services. Their services include assistance with the closing of a May 30, 2014 Amended Stock Purchase Agreement, development of our business plan, accounting services, assisting with regulatory filings and assisting the Company with its capital formation activities.

On August 27, 2014, the Stock Purchase Agreement closed and Stephen Hussey and Kimberly Halvorson joined our management team. On September 13, 2014 John Launie was appointed the Company's Chief Financial Officer.

In November and December 2014, the Company raised \$200,000.00 through a subscription agreement. The Company authorized the issuance of 930,000 shares of restricted Rule 144 common stock. The securities were exempt from registration under Section 4(2) of the Securities Act. All investors were accredited investors and were provided with all requested information before investing.

Part F Exhibits

Exhibit A

Financial Statements until March 31, 2015

Exhibit B

Financial Statements for the year ending December 31, 2014

Exhibit C

Articles of Incorporation

Exhibit D

Corporate By-laws

Item XXI CERTIFICATIONS

I, Chris Swenson certify that:

1. I have reviewed this Initial Disclosure Statement of Emergent Health Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Chris Swenson, CEO